arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

IGC Pharma, Inc.

IGC
$0.18 ▼ -0.01 (-4.09%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
66 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

IGC Pharma, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $18.1M
Dividend Yield —
Revenue Growth -19.2% ↘
Op. Margin None
ROIC -45.4% ↘
FCF / Share $-0.01 ↘
Trailing P/E —
Price / Book 3.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

66-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$265.00K
↓ -19.2% —
Net Income Profit after all expenses
$-2.94M
↓ -83.6% —
Operating Margin Operating profit as % of sales
-427.2%
↓ -1411.0% —
FCF / Share Free cash flow per share
$-0.01
↑ +20.8% —
Long-Term Debt Long-term obligations
$134.00K
↑ +1.5% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
0
Returns ↓
7
Financial Health →
47
Cash Quality ↓
48

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 16 years · 66 quarters